This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 4, 2018.(b)(4).The returned sample was visually inspected and there were no visual anomalies observed on the complaint sample.The outlet end of the ops was left open while submerged under water.The line was pressurized until bubbles could be seen from the outlet of the ops, which occurred at 11 mmhg.This tested the flow of the duck bill, and the specification has a maximum of 99mmhg; the test passed.The duckbill was also functioning as intended with not allowing back flow; positive pressure was released through the positive umbrella at roughly 300 mmhg.The retention sample was evaluated in the same manner and found to meet tcvs specifications for flow of the duckbill.All ops valves undergo 100% leak test and visual inspection.There is a known issue currently ongoing with the duckbill valve within the ops valve, that prevents the duckbill from opening within the product specification range.It is possible that the duckbill valve did not open during inspection, as reported; however, if a high enough pressure had been reached after that initial attempt, the seal in the slit of the duckbill may have been broken, allowing the device to pass all leak tests during the evaluation of the returned sample.This was not able to be confirmed.The cause of the issue with the duckbill is due to a process change at the supplier, specifically during the washing/cleaning step.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|